Advanced search
Publication Cover
Journal of Chemotherapy Latest Articles
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Özgecan Dülgara Department of Medical Oncology, Health Science University, Umraniye Training and Research Hospital, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0678-4024
ORCID Icon,
Sema Türkerb Department of Internal Medicine, Bahcesehir University, Istanbul, Turkey
,
Gül Başaranc Department of Medical Oncology, Acıbadem University, Istanbul, Turkey
,
Murat Arazd Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey
,
Ahmet Taner Sümbüle Department of Medical Oncology, Medical Park Hospital Groups, Adana, Turkey
,
Dilek Çağlayand Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey
,
Özge Gümüşayc Department of Medical Oncology, Acıbadem University, Istanbul, Turkey
,
Sedat Biterf Department of Medical Oncology, Cukurova University, Faculty of Medicine, Adana, Turkey
,
Ahmet Koncag Department of Medical Oncology, Gaziantep Univesity, Sahinbey Training and Research Hospital, Gaziantep, Turkey
,
Miraç Özenh Department of Medical Oncology, Sakarya University, Sakarya, Turkey
,
Hacer Demiri Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey
,
Melek Özdemirj Department of Medical Oncology, Pamukkale University, Denizli, Turkey
,
Fatih Karataşk Department of Medical Oncology, Karabuk University, Karabuk, Turkey
,
Elif Şahinl Department of Medical Oncology, Kocaeli University, İzmit, Turkey
,
Eyyüp Çavdarm Department of Medical Oncology, Tekirdag Namık Kemal University, Tekirdag, Turkey
,
Ayşe İrem Yasinn Department of Medical Oncology, Bezmi Alem Vakıf University, Istanbul, Turkey
,
Alper Yaşaro Department of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey
,
Sümeyra Derinp Department of Medical Oncology, Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
,
Metin Pehlivanq Department of Medical Oncology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey
,
Ümmügül Üyetürkr Department of Medical Oncology, Okan University, Istanbul, Turkey
,
Özlem Özdemirs Department of Medical Oncology, Bozyaka Research and Training Hospital, İzmir, Turkey
,
Erkan Kayıkçıoğlut Department of Medical Oncology, Süleyman Demirel University, Isparta, Turkey
,
Naziye Aku Department of Medical Oncology, Yozgat City Hospital, Yozgat, Turkey
,
Teoman Şakalarv Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaraş, Turkey
,
Abdullah Sakinw Department of Medical Oncology, Medipol University, Istanbul, Turkey
,
Mahmut Büyükşimşekx Department of Medical Oncology, University of Health Sciences-Adana City Training and Research Hospital, Adana, Turkey
,
Seval Ayy Department of Medical Oncology, Balıkesir Atatürk City Hospital, Balıkesir, Turkey
,
İsmail Ertürkz Department of Medical Oncology, Ankara Gulhane Training and Research Hospital, Ankara, Turkey
,
Sinem Akbaşaa Department of Medical Oncology, Koc University, Faculty of Medicine, Istanbul, Turkey
,
Kadriye Bir Yücelab Department of Medical Oncology, Gazi University School of Medicine, Ankara, Turkey
&
Mahmut Gümüşac Department of Medical Oncology, Medeniyet University, Faculty of Medicine, Istanbul, Turkey
 show all
Received 05 Feb 2024, Accepted 05 Jun 2024, Published online: 21 Jun 2024

References

  • Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209. doi:10.1186/bcr3621.
  • Rizzo A, Cusmai A, Acquafredda S, et al. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022;31(6):495–498. doi:10.1080/13543784.2022.2042252.
  • Verma S, Miles D, Gianni L, EMILIA Study Group, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124.
  • Krop IE, Kim S-B, Martin AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–754.
  • Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471. doi:10.1016/S1470-2045(13)70130-X.
  • Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–197.
  • Wolff AC, Hammond MEH, Hicks DG, American Society of Clinical Oncology; College of American Pathologists, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.
  • McKee AE, Farrell AT, Pazdur R, et al. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010;15(suppl. 1):13–18. doi:10.1634/theoncologist.2010-S1-13.
  • Conte B, Fabi A, Poggio F, Gruppo Italiano Mammella (GIM) study group, et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin Breast Cancer. 2020;20(2):e181–e187.
  • Michel LL, Hartkopf AD, Fasching PA, et al. Progression-free survival and overall survival in patients with advanced HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab. Cancers (Basel). 2020;12(10):3021. doi:10.3390/cancers12103021.
  • Noda-Narita S, Shimomura A, Kawachi A, et al. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer. 2019;26(4):492–498. doi:10.1007/s12282-019-00949-4.
  • Battisti NML, Rogerson F, Lee K, et al. Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. Cancer Treat Res Commun. 2020;24:100188.
  • Cortés J, Kim S-B, Chung W-P, DESTINY-Breast03 Trial Investigators, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154. doi:10.1056/NEJMoa2115022.
  • Mamounas EP, Untch M, Mano MS, et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann Oncol. 2021;32(8):1005–1014.
  • Daniels B, Kiely BE, Tang M, et al. Trastuzumab emtansine for HER2-positive metastatic breast cancer: outcomes from a whole-of-population Australian cohort. Breast. 2021;58:106–112. doi:10.1016/j.breast.2021.05.001.
  • Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa1914609.
  • Modi S, Saura C, Yamashita T, DESTINY-Breast01 Investigators, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa1914510.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.